Nature Communications (Feb 2019)

A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host

  • Christian M. Harding,
  • Mohamed A. Nasr,
  • Nichollas E. Scott,
  • Guillaume Goyette-Desjardins,
  • Harald Nothaft,
  • Anne E. Mayer,
  • Sthefany M. Chavez,
  • Jeremy P. Huynh,
  • Rachel L. Kinsella,
  • Christine M. Szymanski,
  • Christina L. Stallings,
  • Mariela Segura,
  • Mario F. Feldman

DOI
https://doi.org/10.1038/s41467-019-08869-9
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 11

Abstract

Read online

Bioconjugation is a promising process to manufacture conjugate vaccines, but currently employed enzymes cannot generate the full spectrum of bacterial glycoproteins. Here, the authors use an O-linking oligosaccharyltransferase to generate a polyvalent pneumococcal bioconjugate vaccine with polysaccharides containing glucose at their reducing end.